Korea Improves New Drug Pricing Incentives After Industry Calls
This article was originally published in PharmAsia News
South Korea’s government is moving to improve reimbursement prices for new drugs developed by domestic companies amid repeated calls from the pharma industry, as part of a series of measures to increase R&D incentives for novel drugs that will be approved locally for the first time in the world.
You may also be interested in...
Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.